Bio Cardia, Inc. BCDA
We take great care to ensure that the data presented and summarized in this overview for BioCardia, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BCDA
Top Purchases
Top Sells
About BCDA
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Insider Transactions at BCDA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 15
2024
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
1,350
+1.27%
|
$1,350
$1.87 P/Share
|
|
Oct 11
2024
|
David Mc Clung Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,565
-27.82%
|
$23,130
$2.65 P/Share
|
|
Oct 11
2024
|
David Mc Clung Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,193
+36.79%
|
$48,386
$2.65 P/Share
|
|
Oct 11
2024
|
Peter Altman President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,680
-17.25%
|
$43,360
$2.65 P/Share
|
|
Oct 11
2024
|
Peter Altman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
44,250
+26.04%
|
$88,500
$2.65 P/Share
|
|
Oct 11
2024
|
Edward M Gillis Senior Vice President, Devices |
SELL
Payment of exercise price or tax liability
|
Direct |
6,840
-35.88%
|
$13,680
$2.65 P/Share
|
|
Oct 11
2024
|
Edward M Gillis Senior Vice President, Devices |
SELL
Grant, award, or other acquisition
|
Direct |
15,808
-45.33%
|
$31,616
$2.65 P/Share
|
|
Sep 03
2024
|
Jim L. Allen Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+31.32%
|
$150,000
$3.0 P/Share
|
|
Sep 03
2024
|
Peter Altman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
41,666
+33.85%
|
$124,998
$3.0 P/Share
|
|
Sep 03
2024
|
Andrew Scott Blank Director |
BUY
Grant, award, or other acquisition
|
Indirect |
111,000
+45.17%
|
$333,000
$3.0 P/Share
|
|
Sep 03
2024
|
David Mc Clung Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,333
+32.41%
|
$24,999
$3.0 P/Share
|
|
Jul 01
2024
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
300
+0.75%
|
$900
$3.05 P/Share
|
|
Jun 28
2024
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
200
+0.5%
|
$400
$2.99 P/Share
|
|
Jun 21
2024
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
500
+1.26%
|
$1,500
$3.29 P/Share
|
|
Jun 14
2024
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
500
+1.27%
|
$1,500
$3.52 P/Share
|
|
Jun 10
2024
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+2.55%
|
$3,000
$3.36 P/Share
|
|
Apr 19
2024
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
2,750
+0.49%
|
$0
$0.37 P/Share
|
|
Mar 28
2024
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
500
+0.09%
|
$0
$0.39 P/Share
|
|
Feb 13
2024
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
108,108
+16.29%
|
$0
$0.46 P/Share
|
|
Jan 19
2024
|
Phillip Md Et Al Frost > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
129,802
-6.41%
|
$0
$0.43 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 279K shares |
|---|---|
| Open market or private purchase | 115K shares |
| Open market or private sale | 130K shares |
|---|---|
| Payment of exercise price or tax liability | 40.1K shares |
| Grant, award, or other acquisition | 15.8K shares |